CIGNA announced a positive coverage policy for minimally invasive sacroiliac (SI) joint fusion exclusive for FDA-cleared implants that are placed across the SI joint to promote bone fusion, such as SI-BONE’s iFuse Implant System.
CIGNA, the fourth-largest U.S. commercial health plan, covers nearly 15 million lives.
“As a result of this positive coverage decision, CIGNA’s members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, President, CEO and Chairman of SI-BONE. “CIGNA’s decision to cover MIS SI joint fusion is a significant milestone in the continuing adoption of this important treatment for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”
As noted in the company’s 3Q19 earnings call, SI-BONE is preparing for an expansion of distribution. The company started 2019 with 67 total sales reps and is on track to have between 102 and 112 total reps by year-end.
CIGNA announced a positive coverage policy for minimally invasive sacroiliac (SI) joint fusion exclusive for FDA-cleared implants that are placed across the SI joint to promote bone fusion, such as SI-BONE's iFuse Implant System.
CIGNA, the fourth-largest U.S. commercial health plan, covers nearly 15 million lives.
“As a result of this...
CIGNA announced a positive coverage policy for minimally invasive sacroiliac (SI) joint fusion exclusive for FDA-cleared implants that are placed across the SI joint to promote bone fusion, such as SI-BONE’s iFuse Implant System.
CIGNA, the fourth-largest U.S. commercial health plan, covers nearly 15 million lives.
“As a result of this positive coverage decision, CIGNA’s members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, President, CEO and Chairman of SI-BONE. “CIGNA’s decision to cover MIS SI joint fusion is a significant milestone in the continuing adoption of this important treatment for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”
As noted in the company’s 3Q19 earnings call, SI-BONE is preparing for an expansion of distribution. The company started 2019 with 67 total sales reps and is on track to have between 102 and 112 total reps by year-end.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.